One of the more controversial and critical parts of Bayer’s $10 billion-plus settlements of Roundup cases last week is a separate deal to resolve future claims that—because it comes in a class action—faces judicial scrutiny and potential objections that may unravel the agreement.

The class action settlement, which includes a $1.1 billion fund, is a key part of Bayer’s strategy to cap its subsidiary Monsanto’s Roundup litigation while keeping its product on store shelves.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]